Home › Activist investors › Resolved campaigns
How campaigns ended, as read from the SEC filings: board seats won in a settlement or at the vote, settlements, board changes the company disclosed, withdrawals, contested votes and offers to acquire. Updated November 20, 2026.
5 of 598 ended campaigns.
| Ended | Activist | Company | Outcome | Detail | Started | Source |
|---|---|---|---|---|---|---|
| Dec 19, 2023 | PL Capital | Banc of California, Inc. | Stake reported below 5% | — | Oct 24, 2016 | Schedule 13D/A |
| Aug 24, 2023 | Sarissa Capital | Alkermes plc. | Stake reported below 5% | — | May 10, 2021 | Schedule 13D/A |
| Jul 21, 2023 | Hudson Executive | ViewRay, Inc. | Stake reported below 5% | — | Feb 24, 2020 | Schedule 13D/A |
| Jul 7, 2023 | Engaged Capital | Quotient Technology Inc. | Stake reported below 5% | — | Nov 17, 2021 | Schedule 13D/A |
| Jun 16, 2023 | Iroquois Capital | PharmaCyte Biotech, Inc. | Stake reported below 5% | — | Jun 23, 2022 | Schedule 13D/A |
An outcome is what the filings show; where nothing was read it is the last status (“No filings in 12 months”). Board seats are counted from the company’s 8-K. Nothing here measures whether a campaign succeeded.